Amgen Inc.
AMGNHealthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024.
- Revenue
- +8.45%
- EPS
- +19.4%
- Free cash flow
- −0.16%
- Total debt
- −1.06%
Quarter to September 2026, against a year earlier
Follow AMGN
Alert me
Amgen Inc. (AMGN) P/E ratio
As of 6 November 2026, Amgen Inc. (AMGN) trades at a P/E ratio of 26.5×. Over the past ten years it has ranged from 13.2× (May 2019) to 75.3× (January 2018); the current reading is higher than 82% of that period. That is in line with the Drug Manufacturers General industry median of 26.5× and above the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 22.8× | (33.22%) |
| FY2024 | 34.2× | 44.46% |
| FY2023 | 23.7× | 10.22% |
| FY2022 | 21.5× | (1.07%) |
| FY2021 | 21.7× | 17.02% |
| FY2020 | 18.6× | (0.31%) |
| FY2019 | 18.6× | 21.35% |
| FY2018 | 15.3× | (77.21%) |
| FY2017 | 67.3× | 360.78% |
| FY2016 | 14.6× | (17.58%) |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 24.2× | 8.62% |
| Jun 2026 | 22.3× | (8.12%) |
| Mar 2026 | 24.3× | 6.38% |
| Dec 2025 | 22.8× | 5.46% |
| 43 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GILD Gilead Sciences, Inc. compare | n/m |
| NVO Novo Nordisk A/S compare | 10.1× |
| BMY Bristol Myers Squibb Company compare | 13.7× |
| AZN AstraZeneca PLC compare | 26.2× |
| AMGN Amgen Inc. | 26.5× |
| NVS Novartis AG compare | 30.9× |
| PFE Pfizer Inc. compare | 41.3× |
| ABBV AbbVie Inc. compare | 50.1× |
| MRK Merck & Co., Inc. compare | 151× |
| Drug Manufacturers General industry median | 26.5× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on AMGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement